As disclosed in the prospectus issued by Ascelia Pharma in connection with the listing on Nasdaq Stockholm in March 2019, CMC SPV was established by Sunstone Life Science Ventures Fund II K/S (“Sunstone”) in April 2017. CMC SPV thereafter acquired all the shares in Ascelia Pharma previously held by Stiftelsen Industrifonden (“Industrifonden”). Sunstone subsequently transferred shares in CMC SPV to parties that participated in an investment round in Ascelia Pharma in June 2017.
In accordance with the agreement entered into between CMC SPV and Industrifonden, CMC SPV was obliged to share certain parts of the proceeds received in connection with future sales of shares in the Company with Industrifonden. The purpose of CMC SPV has been to hold the shares in Ascelia Pharma acquired from Industrifonden and with today’s fulfillment of the payment obligation to Industrifonden, the remaining shares in Ascelia Pharma has been distributed to the shareholders in CMC-SPV.
Prior to the transactions that CMC SPV has now executed, CMC SPV held 2,937,606 shares in Ascelia Pharma, corresponding to approximately 10.2 per cent of the shares in Ascelia Pharma and approximately 10.4 per cent of the votes in Ascelia Pharma.
The private placement, directed to institutional investors, was executed to fund the settlement of CMC SPV’s payment obligations towards Industrifonden and related transaction costs as well as to enable a cash dividend to the shareholders in CMC SPV to fund certain taxes triggered by the distributions. The private placement included 687,606 shares, corresponding to approximately 2.4 per cent of the shares in Ascelia Pharma and approximately 2.4 per cent of the votes in Ascelia Pharma.
The remaining 2,250,000 shares in Ascelia Pharma AB held by CMC SPV, corresponding to approximately 7.8 per cent of the shares in Ascelia Pharma and approximately 8.0 per cent of the votes in Ascelia Pharma, have been distributed to the shareholders in CMC SPV. In connection with this distribution, among others, Sunstone received 290,430 shares, Spogárd Holding A/S (a company controlled by René Spogárd, board member in Ascelia Pharma), received 539,685 shares, Kibegeon ApS (a company controlled by Niels Mengel, board member in Ascelia Pharma), received 112,500 shares, Bo Jesper Hansen (board member in Ascelia Pharma), received 99,855 shares and Magnus Corfitzen (CEO in Ascelia Pharma), received 49,950 shares.
For more information, please contact
Kristian Borbos, CFO
Tel: +46 735 179 113
Mikael Widell, IR & Communications Manager
Tel: +46 703 11 99 60
The information was submitted for publication, through the agency of the contact person set out above, at 8.45pm CET on 14 January 2021.
About Ascelia Pharma
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com.